Mobile

An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjug...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005445-11

An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infants

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that RotaTeq® can be administered concomitantly with MCC vaccine to healthy infants without impairing the antibody seroprotection rate to meningococcal Group C serotype as measured by serum bactericidal antibody with rabbit complement (rSBA) at 28 days following the last dose.

Critère d'inclusion

  • RotaTeq® is indicated for the active immunisation of infants from age of 6 weeks for prevention of gastroenteritis due to rotavirus infection,NeisVac-C® is indicated for active immunisation of children from 2 months of age for the prevention of invasive disease caused by Neisseria meningitidis serogroup C

Liens